

1 **Cohort Profile: A national prospective cohort study of SARS-CoV-2 pandemic outcomes**  
2 **in the U.S. -**

3 **The CHASING COVID Cohort Study**

4 McKaylee M. Robertson<sup>1</sup>, Sarah Gorrell Kulkarni<sup>1</sup>, Amanda Berry<sup>1</sup>, Chloe Mirzayi<sup>1,2</sup>, Madhura  
5 Rane<sup>1</sup>, Mindy Chang<sup>1</sup>, Shivani Kochhar<sup>1</sup>, William You<sup>1</sup>, Andrew Maroko<sup>1,3</sup>, Rebecca Zimba<sup>1</sup>,  
6 Drew Westmoreland<sup>1</sup>, Christian Grov<sup>1,4</sup>, Angela Parcesepe<sup>1,5,6</sup>, Levi Waldron<sup>1,2</sup>, and Denis  
7 Nash<sup>1,2</sup> for the CHASING COVID Cohort Study

8  
9 **Affiliations:**

10 <sup>1</sup>Institute for Implementation Science in Population Health (ISPH), City University of New York  
11 (CUNY); New York City, New York USA

12 <sup>2</sup>Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health  
13 Policy, City University of New York (CUNY); New York City, New York USA

14 <sup>3</sup>Department of Environmental, Occupational, and Geospatial Health Sciences, Graduate  
15 School of Public Health and Health Policy, City University of New York (CUNY); New York  
16 City, New York USA

17 <sup>4</sup>Department of Community Health and Social Sciences, Graduate School of Public Health  
18 and Health Policy, City University of New York (CUNY); New York City, New York USA

19 <sup>5</sup>Department of Maternal and Child Health, Gillings School of Public Health, University of  
20 North Carolina, Chapel Hill, NC, USA

21 <sup>6</sup>Carolina Population Center, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA

22  
23 **WORD COUNT (ABSTRACT):** 300

24 **WORD COUNT (BODY):** 3,994

25  
26 **CONFLICTS OF INTEREST:** None declared

27  
28 **Keywords:** COVID-19; serology, seroconversion, asymptomatic infection, physical distancing;  
29 natural history study, epidemiologic study

30  
31 **CORRESPONDING AUTHOR:**

32 Denis Nash, Ph.D., MPH

33 55 W. 125th St.

34 New York, NY USA 10027.

35 Phone: +1-(917) 740-8714

36 Fax: +1-866-792-7203

37 Email: [denis.nash@sph.cuny.edu](mailto:denis.nash@sph.cuny.edu)

38 Twitter: @epi\_dude

39 **ABSTRACT**

40 **Purpose:** The CHASING COVID Cohort study is a U.S.-based prospective cohort study  
41 launched during the upswing of the U.S. COVID-19 epidemic. The objectives are to: 1) estimate  
42 and evaluate determinants of the cumulative incidence of SARS-CoV-2 infection, disease, and  
43 deaths; 2) assess the impact of the pandemic on psychosocial and economic outcomes; and 3)  
44 assess the uptake of pandemic mitigation strategies.

45 **Participants:** We began enrolling participants March 28, 2020 using internet-based strategies.  
46 Adults  $\geq 18$  years residing anywhere in the U.S. or U.S. territories were eligible. 6,753 people are  
47 enrolled in the cohort, including participants from all 50 U.S. states, the District of Columbia,  
48 Puerto Rico, and Guam. Participants are contacted regularly to complete study assessments,  
49 including interviews and specimen collection.

50 **Findings to date:** Of 4,247 participants who provided a specimen for baseline serologic testing,  
51 135 were seropositive by screening antibody testing (3.2%, 95% CI 2.7%-3.5%) and 90 were  
52 seropositive by confirmatory antibody testing (2.1%, 95% CI 1.7%-2.6%). Cohort data have  
53 been used to assess the role of household crowding and the presence of children in the  
54 household as potential risk factors for severe COVID-19 early in the U.S. pandemic; to describe  
55 the prevalence of anxiety symptoms and its relationship to COVID-19 outcomes and other  
56 potential stressors; and to identify preferences for SARS-CoV-2 diagnostic testing when  
57 community transmission is on the rise via a discrete choice experiment.

58 **Future plans:** The CHASING COVID Cohort Study has outlined a research agenda that  
59 involves ongoing monitoring of the cumulative incidence and determinants of SARS-CoV-2  
60 outcomes, mental health outcomes and economic outcomes. Additional priorities include  
61 COVID-19 vaccine hesitancy, uptake and effectiveness; incidence, prevalence and correlates of  
62 long-haul COVID-19; and the extent and duration of the protective effect of SARS-CoV-2  
63 antibodies.

64

65

66

67

## 68 INTRODUCTION

69 The Coronavirus Disease 2019 (COVID-19) pandemic has dramatically transformed life  
70 across the entire United States, resulting in medical and economic challenges and threats for  
71 individuals, households and communities. The earliest research efforts have focused on  
72 understanding the clinical course of COVID-19 and the most effective ways of treating people  
73 with severe symptoms or illness. As the pandemic progresses, however, we must also  
74 investigate COVID-19's evolving epidemiology and the uptake/impact of non-pharmaceutical  
75 interventions (NPIs)<sup>1</sup>, such as physical distancing, health messaging, and testing on the  
76 cumulative incidence of SARS-CoV-2. Researchers and public health practitioners have called  
77 for cohort studies to describe the community attack rate, as well as how attack rates are  
78 influenced by different approaches to NPI implementation.<sup>2</sup> There is also a need to characterize  
79 both the direct and indirect effects of the SARS-CoV-2 pandemic on mental health and  
80 economic outcomes. Internet-based strategies, which facilitate rapid recruitment of large and  
81 diverse samples, can be leveraged to understand and inform this swiftly changing and  
82 protracted public health crisis.<sup>3,4</sup>

83 In response to the COVID-19 pandemic the CUNY Institute for Implementation Science  
84 in Population Health (ISPH) launched the prospective Communities, Households and  
85 SARS-CoV-2 Epidemiology (CHASING) COVID Cohort study on March 28, 2020. We sought to  
86 prospectively recruit a geographically and socio-demographically diverse cohort of adults (18  
87 years or older) in the United States (U.S.) and U.S. territories in order to contribute to our  
88 understanding of the spread and impact of the SARS-CoV-2 pandemic.

89

## 90 COHORT DESCRIPTION

91            *Objectives and study design.* Key objectives of the cohort study are to: 1. Estimate and  
92 evaluate determinants of the cumulative incidence of SARS-CoV-2 infection, disease, and  
93 deaths; and 2. Assess the pandemic's impact on psychosocial and economic outcomes (mental  
94 health, unemployment, food security); and 3. Assess the uptake of pandemic mitigation  
95 strategies (non-pharmaceutical interventions, testing, contact tracing, isolation/quarantine,  
96 vaccination). The study design is shown in Figure 1. Study visits (completion of questionnaires  
97 online and designated by  $V_x$ ) are completed every 1-3 months following cohort screening and  
98 enrollment, and will continue through December 2021, for a maximum of 21 months follow-up.  
99 Initial specimen collection ( $S_1$ ) occurred during April-June 2020 and the second specimen ( $S_2$ )  
100 will be collected in November 2020-January 2021. Additional specimen collection may occur in  
101 2021, depending on epidemic activity and availability of funding.

102            *Cohort eligibility.* Eligibility was determined during cohort screening visits and cohort  
103 enrollment visits (Figure 2). To be eligible for inclusion in the cohort, individuals had to: 1) reside  
104 in the U.S. or a U.S. territory; 2) be age 18 years or older; 3) provide valid email address; and 4)  
105 demonstrate early engagement in longitudinal study activities, including: a) completion of  $V_1$   
106 (which provided the opportunity to consent for serologic testing); and b) completion of at least  
107 one additional screening visit in addition to  $V_1$  (i.e.,  $V_0$  or  $V_2$ ) or provision of a baseline specimen  
108 for serologic testing ( $S_1$ ).

109            *Cohort screening and enrollment.* Cohort screening and enrollment began on March 28,  
110 2020, at which point there were 122,000 documented COVID-19 cases and 2,200 COVID-19  
111 deaths reported in the U.S..<sup>54</sup> Enrollment ended on August 21, 2020, when there were 783,000  
112 persons diagnosed with SARS-CoV-2, including 42,000 deaths in the U.S..<sup>5</sup>

113            We used internet-based strategies that are effective for recruiting and following large and  
114 geographically diverse online cohorts, including at-home specimen collection.<sup>3,4,6</sup> Persons aged

115 18 years and above who resided in the U.S. or U.S. territories were eligible to join the study.  
116 Study participants were recruited via ads on social media platforms (e.g., Facebook, Instagram,  
117 and Scruff), Qualtrics Panel, or via referral to the study (anyone with knowledge of the study  
118 was allowed to invite others to participate). By relying on personal networks of participants  
119 through referrals, we aimed to bolster recruitment of persons >59 years of age, who were  
120 important to have represented in the cohort because of their risk, but may not be as active on  
121 social media as younger persons. Facebook and Instagram advertisements were developed in  
122 English and Spanish and were geographically targeted to people currently residing in the U.S.  
123 and U.S. territories who were 18 or older.

124 Study staff systematically monitored cohort demographics and proactively adjusted  
125 advertisement strategies as needed to balance geographic and sociodemographic  
126 characteristics of respondents. For example, strategies could shift to prioritize recruitment of  
127 older persons if that demographic was poorly represented.

128 Interested participants were directed to a pre-enrollment survey (hosted by Qualtrics) to  
129 be completed in their web browser on a computer or on a mobile device.<sup>7</sup> A consent form  
130 described the study, plans for follow-up assessments, and future study opportunities, including  
131 the possibility to receive SARS-CoV-2 serologic testing as part of the study. The consent form  
132 also described the incentive schedule: a drawing for \$100 for a pre-enrollment survey ( $V_0$ ) (with  
133 20 winners) and gift cards ranging from \$5-30 for all participants for completion of subsequent  
134 surveys and antibody testing.

135

### 136 *Study measurements*

137 Measures included on the screening, enrollment and follow-up study questionnaires  
138 were derived from previously published research (e.g., *Together 5000*<sup>3</sup>, BRFSS, and H1N1

139 influenza studies<sup>8,9</sup>) and from other researchers who had developed surveys for understanding  
140 COVID-19 (e.g., Canadian Institutes of Health Research<sup>7</sup> and Food Access and Food Security  
141 during COVID-19<sup>10</sup>). Measures were also developed *de novo* in response to the novel  
142 pandemic. The follow-up assessments gather data on symptoms, testing, hospitalizations and  
143 other time-varying factors (see Table 1 for key measurement realms). All study questionnaires  
144 are available on CHASING COVID Cohort Study webpage (<https://cunyisph.org/chasing-covid/>).

145 *Daily symptom tracking.* Study questionnaires are supplemented by voluntary daily  
146 symptom tracking via an innovative COVID-19 symptom tracker<sup>11</sup> that we have deployed in our  
147 cohort. The Coronavirus Pandemic Epidemiology (COPE) consortium<sup>11</sup> has developed the  
148 COVID Symptom Tracker app, which enables individuals to self-report information on COVID-19  
149 via daily prompts for recent symptoms, health care visits, and COVID-19 testing results. The  
150 CHASING COVID Cohort Study joined the COPE consortium on April 6th, allowing our cohort  
151 members who use the app to affiliate with our cohort and consent to have their their app  
152 responses linked with the CHASING COVID Cohort Study data.

153 *Specimen collection for serologic testing.* At the  $V_1$  assessment (end of April, 2020  
154 through July, 2020) and the  $V_4$  assessment (beginning November, 2020), participants were  
155 asked to self-collect a specimen at home for serologic testing. Participants are mailed dried  
156 blood spot (DBS) specimen collection kits. To facilitate self-sampling procedures, all participants  
157 are provided printed instructions and a QR code to view a video demonstrating procedures for  
158 DBS collection, and instructions to contact the study team, if they have questions.<sup>12</sup> DBS cards  
159 are returned via the U.S. Postal Service (self-addressed, stamped envelope containing EBF Foil  
160 biohazard bag™) to the study laboratory (Molecular Testing Labs).<sup>13</sup> Participants receive \$20  
161 upon receipt of a valid specimen by the study laboratory.

162            *Serologic testing.* All DBS specimens are screened for SARS-CoV-2 antibodies using  
163 the Biorad total antibody test, and specimens that are reactive are tested further using the  
164 Euroimmun IgG test. Once tested, DBS specimens are banked at -80°C for future SARS-CoV-2  
165 studies.

166

#### 167 *Data management and analysis*

168            All data were imported and cleaned in R and SAS (V9.4). Data were geocoded based on  
169 a self-reported ZIP code. Maps were created in ArcGIS 10.7. Data from  $V_1$  were used to compile  
170 summary statistics on baseline characteristics.

171

#### 172 *Ethical Approval*

173            The study protocol was approved by the Institutional Review Board at the City University  
174 of New York (CUNY) Graduate School for Public Health and Health Policy.

175

#### 176 *Cohort Eligibility*

177            Of the 10,803 individuals who completed at least one study screening or enrollment visit,  
178 10,714 were age 18 or older, U.S. residents, and provided a valid email address for study  
179 follow-up. Of those, 7,246 completed  $V_0$ , 6,829 completed  $V_1$ , 5,101 completed  $V_2$ , 6,482  
180 consented to provide a baseline DBS specimen; 6,753 met final study eligibility criteria of  
181 completing 2 of 3 screening/enrollment visits or consenting to provide a specimen as part of  $V_1$ ,  
182 and were considered enrolled in the cohort (Figure 2). Participants who only completed  $V_1$  are  
183 routinely invited to complete additional study assessments and specimen collection.

184

#### 185 **FINDINGS TO DATE**

## 186 *Cohort Characteristics*

187           The cohort includes 6,753 participants from all 50 states, the District of Columbia, Puerto  
188 Rico and Guam (Figure 3). At  $V_1$ , the median age of participants was 37 years (interquartile  
189 range: 29, 51); 73% were aged 18-49 (including 5% <21 years (N=370)), 12% were aged 50-59,  
190 and 15% were aged 60 years or older (Table 2). Just under half (45%) were male, 20% were  
191 Hispanic, 13% black non-Hispanic, 7% Asian or Pacific Islander, and 57% white non-Hispanic. A  
192 majority were currently employed (63%), 10% were retired, 13% were out of work, and 9% were  
193 students.

194           More than half (56%) were considered to be at increased risk for severe COVID-19  
195 disease should they become infected with SARS-CoV-2, on the basis of age (60+), presence of  
196 an underlying health condition (chronic lung disease, asthma [current], type 2 diabetes, serious  
197 heart condition, kidney disease, or an immunocompromised status), or daily smoking (Table 2).  
198 The proportion of persons with an underlying health condition increased with age category (32%  
199 among 18-49 year olds and 65% among 60+), and the proportion of daily smokers decreased  
200 with increasing age category (20% and 9%, respectively).

201           15% of participants reported being an essential worker (Table 2). By employment  
202 category, 12% were healthcare workers (half of whom reported screening or caring for  
203 COVID-19 patients), 1.5% worked in delivery services (e.g., food) and less than 1% worked in  
204 transportation (e.g., taxis). The proportion of persons employed in essential work decreased  
205 with increasing category of age.

206           *NPI / Physical Distancing Behaviors Stratified by Age Categories.* A high proportion of  
207 participants reported avoiding large groups with >20 people in the prior two weeks and avoiding  
208 handshakes or hugs (89% and 88%, respectively) (Table 3). One-quarter (25%) reported  
209 working from home. A majority reported wearing gloves (58%) and masks (93%), and these



210 proportions significantly increased with age (57% of 18-49 year olds wore gloves versus 60% of  
211 60+, and 92% of 18-49 year olds wore masks versus 95% of 60+, p for chi-square: <0.001 for  
212 each comparison). Almost one in three (29%) participants reported stockpiling personal  
213 protective equipment and 39% reported stockpiling food. The proportion of participants who  
214 reported stockpiling decreased significantly with increasing age categories (31% of 18-49 year  
215 olds stockpiled PPE versus 24% of 60+, and 42% of 18-49 year olds stockpiled food versus  
216 29% of 60+, p<0.001 for each comparison).

217 *COVID-19 symptoms and care outcomes.* One in six (17% or N = 1,143) reported any  
218 COVID-like symptoms in the month prior to Visit 1 (cough, fever or shortness of breath) and this  
219 decreased significantly with age (19% versus 11% among 18-49 and 60+ year olds, respectively  
220 and p<0.001) (Table 3). The most common symptoms reported were new cough (10%) followed  
221 by shortness of breath (7%) and fever (5%). Among the 17% of participants reporting  
222 COVID-like symptoms (N = 1,143), 35% (N = 396) said they called or saw a  
223 physician/healthcare professional and 8% (N = 87) were hospitalized (Table 4). Compared to  
224 participants at lower risk for COVID-19 illness, participants with higher risk for severe COVID-19  
225 illness were more likely to report seeing a physician or hospitalization (28% versus 38% and 2%  
226 versus 10%, respectively and p <0.001 for each comparison). Among all participants, 12% (N =  
227 836) reported being tested for COVID-19 and 4% (N = 268) reported receiving a COVID-19  
228 diagnosis. Participants at higher risk for COVID-19 illness were significantly more likely to report  
229 testing or receiving a diagnosis than participants at lower risk for severe COVID-19 illness  
230 (testing: 14% versus 10% and diagnosis: 5% versus 2%, respectively and p<0.001 for each  
231 comparison).

232 *Baseline serologic testing.* 4,247 of 6,482 consenting participants (65.5%) provided a dried  
233 blood spot specimen for serologic testing, of whom 135 (3.2%, 95% CI 2.7%-3.5%) were

234 positive by screening and 90 (2.1%, 95% CI 1.7%-2.6%) by confirmatory serologic testing.

235 While differences were not statistically significant, seropositive persons by either test tended to  
236 be younger, male, and from the northeast U.S.

237 *Household factors and the risk of severe COVID-like illness early in the U.S. pandemic.*<sup>14</sup>

238 Early in the U.S. pandemic, crowded indoor settings and sustained close indoor contact without  
239 masks were associated with an increased likelihood of SARS-CoV-2 spread. The role of such  
240 exposures, as well as the role of the presence of children in the household have not been  
241 investigated as risk factors for severe COVID-like illness (i.e., hospitalization). We found that the  
242 risk of hospitalization due to COVID-19 was higher among participants who had (versus those  
243 who did not have) children in the home, with an adjusted odds ratio [aOR] of hospitalization of  
244 10.5 (95% CI 5.7-19.1) among study participants living in multi-unit dwellings and 2.2 (95% CI  
245 1.2-6.5) among those living in single unit dwellings. Among participants living in multi-unit  
246 dwellings, the aOR for COVID-19 hospitalization among participants with more than 4 persons  
247 in their household (versus 1 person) was 2.5 (95% CI 1.0- 6.1), and 0.8 (95% CI 0.15-4.1)  
248 among those living in single unit dwellings. This work demonstrated that, early in the U.S.  
249 SARS-CoV-2 pandemic, certain household exposures likely increased the risk of both  
250 SARS-CoV-2 acquisition and the risk of severe COVID-19 disease requiring hospitalization.  
251 These findings may have implications for mask wearing and other mitigation strategies at home  
252 during the initial phase of future 'stay at home' orders.

253 *The relationship between anxiety, health, and potential stressors among adults in the United*

254 *States during the early phase of the COVID-19 pandemic.*<sup>15</sup> Epidemiologic data on the mental  
255 health impact of the COVID-19 pandemic in the U.S. remains limited. We found that more than  
256 one-third (35%) of individuals reported moderate or severe anxiety symptoms at cohort  
257 screening/enrollment visits. Having lost income due to COVID-19 (adjusted prevalence ratio

258 [aPR] 1.27 (95% Confidence Interval [CI] 1.16, 1.30), having recent COVID-like symptoms (aPR  
259 1.17 (95% CI 1.05, 1.31), and having been previously diagnosed with depression (aPR 1.49,  
260 (95% CI 1.35, 1.64) were positively associated with moderate or severe anxiety symptoms. This  
261 work demonstrated that anxiety symptoms were common and appear to be elevated among  
262 adults in the U.S. during the early phase of the COVID-19 pandemic. Strategies to screen and  
263 treat individuals at increased risk of anxiety, such as individuals experiencing financial hardship  
264 and individuals with prior diagnoses of depression, should be developed and implemented.

265 *SARS-CoV-2 Testing Service Preferences of Adults in the United States: Discrete Choice*  
266 *Experiment*<sup>16</sup> and *Patterns of SARS-CoV-2 testing preferences in a national cohort in the United*  
267 *States*.<sup>17</sup> A discrete choice experiment (DCE) was used to assess the relative importance of  
268 type of SARS-CoV-2 test, specimen type, testing venue, and results turnaround time.  
269 Turnaround time for test results had the highest relative importance (30.4%), followed by test  
270 type (28.3%), specimen type (26.2%), and venue (15.0%). Participants preferred fast results on  
271 both past and current infection and using a noninvasive specimen, preferably collected at home.  
272 Simulations suggested that providing immediate or same day test results, providing both PCR  
273 and serology, or collecting oral specimens would substantially increase testing uptake over the  
274 current typical testing option. Using latent class analysis, we also found five distinct patterns in  
275 testing preferences in the cohort, including groups of ‘comprehensive testers’, ‘fast-track  
276 testers’, ‘dual testers’, ‘non-invasive, dual testers’, and ‘home testers’.<sup>17</sup> We concluded that  
277 testing strategies that offer account for preferences and their heterogeneity would likely have  
278 the most uptake and engagement among residents in communities with increasing community  
279 transmission of SARS-CoV-2.

280

281 **Future plans**

282           The CHASING COVID Cohort Study will continue to conduct ongoing monitoring of the  
283 cumulative incidence and determinants of SARS-CoV-2 outcomes (including mortality), mental  
284 health outcomes (e.g., anxiety and depression) and economic outcomes (e.g., income loss, food  
285 security), as well as overall and cause-specific mortality. A number of longitudinal analyses are  
286 ongoing or planned using the data that have already been collected, with priorities including  
287 those related to COVID-19 vaccine hesitancy, uptake and effectiveness; NPI engagement  
288 before and after vaccination; incidence, prevalence and correlates of long-haul COVID-19;  
289 extent and duration of protective effect of SARS-CoV-2 antibodies.

290

## 291 **DISCUSSION**

292           This longitudinal cohort study enrolled 6,753 persons from all 50 U.S. states, the District  
293 of Columbia, Puerto Rico and Guam, and was rapidly established during the upswing of the  
294 SARS-CoV-2 pandemic in the U.S. The cohort is geographically and socio-demographically  
295 diverse, and includes participants from many active hotspots, as well as health care workers  
296 and other essential workers, and individuals who are vulnerable to severe outcomes associated  
297 with SARS-CoV-2 infection. Initial serologic testing indicates that the cohort overwhelmingly had  
298 no evidence of prior SARS-CoV-2 infection at the time of specimen collection, suggesting a high  
299 potential for observing subsequent seroconversions, and the extent of protective effects of new  
300 vaccines.

301           At cohort screening/enrollment, nearly one in six participants (17%) reported having had  
302 recent COVID-like symptoms. However, only small proportions of participants reported having  
303 been tested for or diagnosed with SARS-CoV-2 (12% and 4%, respectively). Participants with  
304 elevated risk for COVID-19 illness were more likely to report seeking care, hospitalization, and  
305 testing than participants without elevated risk. This is consistent with both the recommendations

306 for testing and care seeking during the late spring and early summer of 2020, as well as the  
307 relative lack of SARS-CoV-2 testing availability in most parts of the U.S.

308         Recent evidence of waning of SARS-CoV-2 antibodies to both nucleocapsid and spike  
309 proteins, combined with the timing of specimen collection for many participants in our cohort,  
310 make our serology-based proxy measure for the cumulative incidence of SARS-CoV-2 infection  
311 challenging to interpret.<sup>18</sup> Since SARS-CoV-2 antibodies may wane with time, and waning may  
312 be faster for antibodies to the nucleocapsid protein of the SARS-CoV-2 virus<sup>19</sup>, we have likely  
313 underestimated the cumulative incidence of infection in the cohort leading up to enrollment.  
314 Subsequent antibody testing in our cohort ( $S_2$ ) will help clarify whether participants who were  
315 positive on the screening test for total SARS-CoV-2 antibodies and negative on the follow-up  
316 IgG test represent early infections or false positives. However, antibody waning may also make  
317 this interpretation challenging, as up to 5 months may have passed between the first and  
318 second specimen collection for some participants. Recently, other teams have developed  
319 algorithms to correct seroprevalence estimates for waning<sup>20</sup>, and we may be able to use these  
320 approaches to correct our estimates of cumulative incidence in our cohort going forward.  
321 Limitations of serological assays notwithstanding<sup>21</sup>, recent cross-sectional serosurveys done  
322 prior to the relaxing of physical distancing have reported cumulative incidence estimates ranging  
323 from 1.7% in Indiana to 21% in New York City, and <10% nationally as of the end of September  
324 2020.<sup>18,22–26</sup>

325         Strengths of our cohort study include its prospective design, allowing direct observation  
326 of seroconversions and incident COVID-19 disease among those who were unexposed and/or  
327 disease free at enrollment. We also have been able to include a range of relevant measures, for  
328 a more comprehensive view of the impact of the pandemic and its response on several  
329 outcomes in addition to SARS-CoV-2 infection, including mental health and economic

330 outcomes, vaccine uptake, and long-haul COVID. The longitudinal design also allows  
331 prospective estimation of the incidence of COVID-19 disease among those with antibodies to  
332 SARS-CoV-2, allowing assessment of the extent to which SARS-CoV-2 antibodies, acquired  
333 through natural infection or through vaccination, offer short-term protection against subsequent  
334 disease. Prospective studies are complementary to, and offer some strengths over, cross  
335 sectional studies, especially in the context of rapidly evolving emergencies and the associated  
336 public health response. While repeat cross-sectional surveys are valuable in a pandemic,  
337 including their ability to assess trends in many important outcomes, they cannot assess what  
338 factors may influence change over time in an individual's or a household's exposures and  
339 outcomes.

340 Our study includes those who recover from SARS-CoV-2 infection (asymptomatic or  
341 mild) and COVID-19 disease, and follows these individuals over time to characterize their  
342 recovery, including persistence of symptoms, onset and persistence of new symptoms, and  
343 persistence of antibodies. This will allow us to characterize of the epidemiology of long-haul  
344 COVID (aka post-acute covid syndrome or PACS).<sup>27</sup> We will also be able to assess mortality  
345 and related risk factors via matching with the US National Death Index.<sup>28</sup>

346 Our approach employs protocols for overcoming common pitfalls of fully online studies  
347 (e.g., repeat/duplicate participation). Our online, volunteer recruitment approach allows us to  
348 sample individuals who may not be reached by traditional telephone recruitment approaches,  
349 which can have very low response rates. As part of our enrollment procedures, we record IP  
350 address, email addresses, participant contact information, and require participants to have valid  
351 U.S. mailing addresses (required for those who opt to receive an at-home SARS-CoV-2  
352 specimen collection kit). Participants are "known" to the research team (name, email, address),  
353 thus averting some of the traditional shortcomings of online-only studies (particularly

354 anonymous, cross-sectional online studies).

355           Our cohort study has limitations worth noting, as they inform what can and cannot be  
356 assessed. First, while our study is national in scope, we will be unable to provide estimates of  
357 seroprevalence and cumulative incidence that are representative of that of the U.S. population.  
358 Second, we will likely underestimate the incidence of COVID-19 related hospitalizations. Most  
359 research studies deployed in the middle of a pandemic, including ours, will by definition,  
360 produce some biased estimates since they will not include some information on participants who  
361 died from COVID-19, were hospitalized with COVID-19 after recruitment and were either lost to  
362 follow-up or were too sick to participate in the research activities. We will ascertain deaths in our  
363 participants using the National Death Index. Additionally, from published studies, we will  
364 routinely assess bias in our estimates due to these factors and adjust them accordingly when  
365 possible. Third, we will largely be unable to conduct state or county specific analyses, except for  
366 a few localities with high participation (e.g., New York, Texas, Florida and California). Finally,  
367 although our sample is not representative of the entire U.S. population, it is geographically  
368 representative and socio-demographically diverse. Our study will complement other efforts and  
369 approaches to address similar research questions, such as the NIH's national study<sup>29</sup>, and the  
370 COVID-Vu study.<sup>30</sup> Indeed, it will be important to assess the extent to which the different  
371 strategies used in each of these cohort studies reach similar or divergent conclusions.

372

### 373 **Collaboration, data sharing, and dissemination of findings**

374           We will post a deidentified, HIPAA compliant, public use version of Visit 1 and follow-up  
375 data on GitHub.<sup>31</sup> Data will be presented as flat text files (CSV) formatted for compatibility with  
376 county-level longitudinal case load datasets, including date, county, state, and fips code. We will

377 continue to provide direct feedback to our cohort and other stakeholders who have signed up for  
378 updates via follow-up emails to participants, and the CUNY ISPH study website.<sup>32</sup>

379

## 380 **Conclusion**

381 A geographically and socio-demographically diverse group of participants, largely  
382 without serologic evidence of prior SARS-CoV-2 infection, was rapidly enrolled into a national  
383 longitudinal cohort study during the upswing of the SARS-CoV-2 pandemic in the U.S. Strengths  
384 of the study include the potential for direct observation of seroconversions and incident  
385 COVID-19 disease in areas of active transmission, and related determinants. The study is also  
386 examining a range of other outcomes, including psychosocial and employment outcomes, and  
387 long-haul COVID. The study has the potential to monitor and assess the uptake and impact of  
388 the public health response to control and mitigate the SARS-CoV-2 pandemic in the U.S.,  
389 including the uptake of recently authorized vaccines.

390

## 391 **Contributors**

392 MMR, SGK, CG and DN conceptualized the study. SK, MC and MMR performed statistical  
393 analyses. MR and DN wrote the first draft of the paper. MMR, SGK, AB, CM, SK, MR, WY, AM,  
394 RZ, DW, CG, AP, LW, and DN contributed to interpreting the data and to the writing and revising  
395 of the manuscript.

396

## 397 **Acknowledgements**

398 The authors wish to thank the participants of the CHASING COVID Cohort Study. We are  
399 grateful to you for your contributions to the advancement of science around the SARS-CoV-2  
400 pandemic.



401

402 **Funding**

403 Funding for this project is provided by The National Institute for Allergies and Infectious  
404 Diseases (NIAID), award number 3UH3AI133675-04S1 (MPIs: D Nash and C Grov), the  
405 CUNY Institute for Implementation Science in Population Health ([cunyisph.org](http://cunyisph.org)) and the  
406 COVID-19 Grant Program of the CUNY Graduate School of Public Health and Health Policy,  
407 and NICHD grant P2C HD050924 (Carolina Population Center).

408

409

410 **Table 1: Realms of Measurement in the CHASING COVID Cohort**

411

	Measure	Cohort screening (V0)	Cohort enrollment (V1)	Follow-up (V2)	Follow-up (V3)	Parents
Individual and household characteristics	Sociodemographics (various measures)	✓	✓	✓		✓
	Household size and age distribution	✓				✓
	Educational/childcare experience of household children				✓	✓
	Height and weight			✓		
	Employment status	✓	✓	✓	✓	✓
	Food and housing security		✓	✓		
COVID-19 risk factors	Pre-existing/co-morbid conditions	✓				
	Smoking and vaping behaviors	✓				✓
	Essential employee status*	✓	✓	✓	✓	
	NPI uptake and other precautions	✓	✓	✓	✓	
	Influence of social media on COVID knowledge and beliefs	✓	✓			
	Understanding of epidemiological concepts (antibodies, herd immunity)				✓	
Health care-related	Health care access and insurance status	✓	✓	✓	✓	
	Sexual and reproductive health				✓	
COVID-19-related outcomes	Recent COVID-like symptoms	✓	✓	✓	✓	
	Medical care for COVID-like symptoms	✓	✓	✓	✓	
	Recent SARS/COV2 testing** and diagnosis	✓	✓	✓	✓	
	Contact tracing***, quarantine, and isolation			✓	✓	
	Serology (SARS/COV2 IgM and IgG)		✓			
	Vaccine uptake			✓	✓	
Mental and physical health	Anxiety (GAD-7) and risk perceptions	✓	✓	✓	✓	✓
	Depression (PHQ8)		✓	✓		✓
	PTSD (PC-PTSD-5)					✓
	Resilience, stress, and coping					✓
	Social support		✓	✓	✓	✓
	IPV		✓	✓	✓	
	Drug use		✓			✓
	Alcohol use (AUDIT)		✓			✓
	Physical Activity				✓	

412

\*front-line health care workers, hospital staff, first responders, grocery clerks, delivery workers, educators (V3 only)

\*\* V3 covers testing experience and expanded testing questions

\*\*\* V3 covers informal contact tracing as well as onward transmission

413 **TABLE 2: Characteristics of CHASING COVID Cohort**

	Total		18-49		50-59		60+		Chi-square
	N	%	N	%	N	%	N	%	p-value
<b>Total</b>	<b>6,753</b>	<b>100</b>	<b>4,931</b>	<b>100</b>	<b>797</b>	<b>100</b>	<b>1,025</b>	<b>100</b>	
Age (Median, IQR)	37 (29, 51)		33 (27, 39)		54 (51, 57)		66 (63, 71)		
<b>Gender</b>	<b>&lt;0.0001</b>								
Male	3,070	45	2,274	46	374	47	422	41	
Female	3,516	52	2,503	51	413	52	600	59	
Transgender/Non-Binary	167	2	154	3	10	1	3	0	
<b>Race/Ethnicity</b>	<b>&lt;0.0001</b>								
Hispanic	1,326	20	1,152	23	102	13	72	7	
Black NH	911	13	764	15	92	12	55	5	
Asian/Pacific Islander	462	7	420	9	20	3	22	2	
White NH	3,837	57	2,431	49	558	70	848	83	
Other	217	3	164	3	25	3	28	3	
<b>Employment</b>	<b>&lt;0.0001</b>								
Employed	4,254	63	3,389	69	527	66	338	33	
Out of work	869	13	676	14	128	16	65	6	
Homemaker	355	5	280	6	51	6	24	2	
Student	574	9	562	11	10	1	2	0	
Retired	698	10	21	0	81	10	596	58	
Missing	3	0	3	0	0	0	0	0	
<b>Income</b>	<b>&lt;0.0001</b>								
<\$50,000	2,715	40	2,083	42	276	35	356	35	
\$50,000 to \$99,999	2,034	30	1,467	30	234	29	333	32	
\$100,000+	1,803	27	1,216	25	276	35	311	30	
Missing	201	3	165	3	11	1	25	2	
<b>Region</b>	<b>0.0154</b>								
Midwest	1,135	17	813	16	136	17	186	18	
Northeast	1,896	28	1,347	27	251	31	298	29	
South	2,072	31	1,552	31	229	29	291	28	
West	1,642	24	1,216	25	180	23	246	24	
US Dependent	8	0	3	0	1	0	4	0	
<b>Urban area</b>	<b>2,904</b>	<b>43</b>	<b>2,233</b>	<b>45</b>	<b>318</b>	<b>40</b>	<b>353</b>	<b>34</b>	<b>&lt;0.0001</b>
<b>High Risk for Severe COVID-19<sup>1</sup></b>	<b>3,764</b>	<b>56</b>	<b>2,271</b>	<b>46</b>	<b>468</b>	<b>59</b>	<b>1,025</b>	<b>100</b>	<b>&lt;0.0001</b>
<b>Any Underlying Health Condition<sup>2</sup></b>	<b>2,637</b>	<b>39</b>	<b>1,557</b>	<b>32</b>	<b>412</b>	<b>52</b>	<b>668</b>	<b>65</b>	<b>&lt;0.0001</b>
<b>Smoker<sup>3</sup></b>	<b>1,203</b>	<b>18</b>	<b>985</b>	<b>20</b>	<b>121</b>	<b>15</b>	<b>97</b>	<b>9</b>	<b>&lt;0.0001</b>
<b>Essential Worker</b>	<b>1,021</b>	<b>15</b>	<b>862</b>	<b>17</b>	<b>101</b>	<b>13</b>	<b>58</b>	<b>6</b>	<b>&lt;0.0001</b>
All Healthcare Workers (HCW)	809	12	690	14	73	9	46	4	<0.0001
HCW Who Screen or Care for COVID-19 Patients	403	6	357	7	32	4	14	1	<0.0001
Law Enforcement	33	0	23	0	8	1	2	0	0.0047
Emergency Response	23	0	19	0	3	0	1	0	0.3492
Delivery (e.g. food)	101	2	96	2	3	0	2	0	<0.0001
Transportation (e.g. taxi or airline)	55	1	34	1	14	2	7	1	0.0070

1. High risk for severe illness included people 60 years or older or reporting any underlying health condition, daily smoking or screening or providing care for COVID-19 patients

2. Any underlying health condition includes people who reported chronic lung disease, asthma (current), type 2 diabetes, serious heart condition (history of MI, angina, or CHD), kidney disease, HIV or immunocompromised

3. People who report they smoke cigarettes or e-cigarettes daily

414

415 **Table 3: Behaviors and Symptoms by Age Category of CHASING COVID Cohort**

	Total		18-49		50-59		60+		Chi-Square
	N	%	N	%	N	%	N	%	P-value
<b>Total</b>	6,753	100	4,931	100	797	100	1,025	100	
<b>Behaviors in the past month</b>									
Avoided Groups >20	6,025	89	4,337	88	734	92.1	954	93	<0.0001
Avoided Handshakes	5,969	88	4,272	87	746	93.6	951	93	<0.0001
Bought Firearm	382	6	357	7	15	1.88	10	1	<0.0001
Worked from Home	1,673	25	1,413	29	158	19.82	102	10	<0.0001
Wore Gloves	3,920	58	2,831	57	474	59.47	615	60	0.2137
Wore Mask	6,250	93	4,520	92	753	94.48	977	95	<0.0001
Stockpiled PPE	1,948	29	1,536	31	169	21.2	243	24	<0.0001
Stockpiled Food	2,659	39	2,089	42	268	33.63	302	29	<0.0001
Quarantined	4,282	63	3,237	66	449	56.34	596	58	<0.0001
<b>Symptoms since last survey/in past month</b>									
Covid-like symptoms (cough, fever, or shortness of breath)	1,143	17	918	19	117	14.68	108	11	<0.0001
New Cough	664	10	553	11	57	7.15	54	5	<0.0001
Fever	312	5	260	5	33	4.14	19	2	<0.0001
Shortness Breath	488	7	376	8	52	6.52	60	6	0.0984
Coughing Blood	52	1	50	1	--	--	2	0	0.0007

416

417


418 **Table 4: CHASING COVID Cohort Care Outcomes Stratified by Risk for Severe COVID-19**

419 **Illness**


Variable	Overall		No		Yes		Chi-Square p-value
	N	%	N	%	N	%	
All with COVID-like symptoms: cough, fever, or shortness of breath	1,143	100	366	32	777	68	
<b>Saw Physician</b>							<b>0.0042</b>
Yes	396	35	102	28	294	38	
No	741	65	262	72	479	62	
Missing	6	1	2	1	4	1	
<b>Hospitalized</b>							<b>&lt;0.0001</b>
Yes	87	8	7	2	80	10	
No	1,054	92	358	98	696	90	
Missing	2	0	1	0	1	0	
All Participants	6,753	100	2,989	100	3,764	100	
<b>Tested</b>							<b>&lt;0.0001</b>
Yes	836	12	291	10	545	14	
No, but tried to be tested	743	11	290	10	453	12	
No, did not need to be tested	5,134	76	2,389	80	2,745	73	
Missing	40	1	19	1	21	1	
<b>COVID-19 Diagnosis</b>							<b>&lt;0.0001</b>
Yes	268	4	68	2	200	5	
No	605	9	238	8	367	10	
Don't know	26	0	12	0	14	0	
Missing	5,854	87	2,671	89	3,183	85	

420

421 **Figure 1: Design for the CHASING COVID Cohort Study**



423 **Figure 2. Enrollment and follow-up in the CHASING COVID Cohort**




425

426 **Figure 3. Geographic distribution of CHASING COVID Cohort participants by county of**  
427 **residence, N = 6,753**

428

429





## 430 REFERENCES

- 431 1. Hutchins HJ, Wolff B, Leeb R, et al. COVID-19 Mitigation Behaviors by Age Group - United  
432 States, April-June 2020. *MMWR Morb Mortal Wkly Rep* 2020;69(43):1584–90.
- 433 2. Lipsitch M, Swerdlow DL, Finelli L. Defining the epidemiology of Covid-19—studies needed.  
434 *N Engl J Med* 2020;382(13):1194–6.
- 435 3. Grov C, Westmoreland DA, Carneiro PB, et al. Recruiting vulnerable populations to  
436 participate in HIV prevention research: findings from the Together 5000 cohort study  
437 [Internet]. *Annals of Epidemiology*. 2019;35:4–11. Available from:  
438 <http://dx.doi.org/10.1016/j.annepidem.2019.05.003>
- 439 4. Nash D, Stief M, MacCrate C, et al. A Web-Based Study of HIV Prevention in the Era of  
440 Pre-Exposure Prophylaxis Among Vulnerable HIV-Negative Gay and Bisexual Men,  
441 Transmen, and Transwomen Who Have Sex With Men: Protocol for an Observational  
442 Cohort Study [Internet]. *JMIR Research Protocols*. 2019;8(9):e13715. Available from:  
443 <http://dx.doi.org/10.2196/13715>
- 444 5. COVID-19 United States Cases by County [Internet]. Johns Hopkins Coronavirus Resource  
445 Center. [cited 2020 Apr 23]; Available from: <https://coronavirus.jhu.edu/us-map>
- 446 6. Grov C, Westmoreland D, Rendina J, Nash D. Seeing is believing? Unique capabilities of  
447 internet-only studies as a tool for implementation research on HIV prevention for men who  
448 have sex with men: A review of studies and methodological considerations. *JAIDS* 2019; In  
449 press.
- 450 7. Qualtrics XM - Experience Management Software [Internet]. Qualtrics. 2015 [cited 2020 Apr  
451 26]; Available from: <https://www.qualtrics.com/>
- 452 8. Santibanez TA, Singleton JA, Santibanez SS, Wortley P, Bell BP. Socio-demographic  
453 differences in opinions about 2009 pandemic influenza A (H1N1) and seasonal influenza  
454 vaccination and disease among adults during the 2009--2010 influenza season. *Influenza  
455 Other Respi Viruses* 2013;7(3):383–92.
- 456 9. Kumar S, Quinn SC, Kim KH, Daniel LH, Freimuth VS. The impact of workplace policies  
457 and other social factors on self-reported influenza-like illness incidence during the 2009  
458 H1N1 pandemic. *Am J Public Health* 2012;102(1):134–40.
- 459 10. Niles MT, Neff R, Biehl E, Bertmann F, Morgan EH, Wentworth T. Food Access and Security  
460 During Coronavirus Survey- Version 1.0 [Internet]. 2020; Available from:  
461 <https://doi.org/10.7910/DVN/RQ6NMG>
- 462 11. Drew DA, Nguyen LH, Steves CJ, et al. Rapid implementation of mobile technology for  
463 real-time epidemiology of COVID-19. *medRxiv* 2020;2020.04.02.20051334.
- 464 12. How To Collect Blood with Dry Blood Spot Kit - Molecular Testing Labs [Internet]. Molecular  
465 Testing Labs. [cited 2020 Apr 13]; Available from:

- 466 <https://moleculartestinglabs.com/how-to-collect/>
- 467 13. Home - Molecular Testing Labs [Internet]. Molecular Testing Labs. [cited 2020 Apr  
468 26]; Available from: <https://moleculartestinglabs.com/>
- 469 14. Nash D, Qasmieh S, Robertson M, et al. Household factors and the risk of severe  
470 COVID-like illness early in the US pandemic. medRxiv [Internet] 2020; Available from:  
471 <http://dx.doi.org/10.1101/2020.12.03.20243683>
- 472 15. Parcesepe AM, Robertson M, Berry A, et al. The relationship between anxiety, health, and  
473 potential stressors among adults in the United States during the COVID-19 pandemic.  
474 medRxiv [Internet] 2020; Available from: <http://dx.doi.org/10.1101/2020.10.30.20221440>
- 475 16. Zimba R, Kulkarni S, Berry A, et al. SARS-CoV-2 Testing Service Preferences of Adults in  
476 the United States: Discrete Choice Experiment. JMIR Public Health Surveill  
477 2020;6(4):e25546.
- 478 17. Romo ML, Zimba R, Kulkarni S, et al. Patterns of SARS-CoV-2 testing preferences in a  
479 national cohort in the United States. medRxiv [Internet] 2020; Available from:  
480 <https://www.medrxiv.org/content/10.1101/2020.12.22.20248747v1.abstract>
- 481 18. Bajema KL, Wiegand RE, Cuffe K, et al. Estimated SARS-CoV-2 Seroprevalence in the US  
482 as of September 2020. JAMA Intern Med [Internet] 2020; Available from:  
483 <http://dx.doi.org/10.1001/jamainternmed.2020.7976>
- 484 19. Murrell I, Forde D, Tyson L, et al. A longitudinal comparison of spike and nucleocapsid  
485 SARS-CoV-2 antibody responses in a tertiary hospital's laboratory workers with validation  
486 of DBS specimen analysis. medRxiv 2020;2020.10.29.20219931.
- 487 20. Shioda K, Lau MS, Kraay AN, et al. Estimating the cumulative incidence of SARS-CoV-2  
488 infection and the infection fatality ratio in light of waning antibodies. medRxiv [Internet]  
489 2020; Available from: <http://dx.doi.org/10.1101/2020.11.13.20231266>
- 490 21. Milani GP, Dioni L, Favero C, et al. Serological follow-up of SARS-CoV-2 asymptomatic  
491 subjects. Sci Rep 2020;10(1):20048.
- 492 22. Cuomo Says 21% of Those Tested in N.Y.C. Had Virus Antibodies [Internet]. New York  
493 Times. 2020 [cited 2020 Apr 25]; Available from:  
494 <https://www.nytimes.com/2020/04/23/nyregion/coronavirus-new-york-update.html>
- 495 23. Bendavid E, Mulaney B, Sood N, et al. COVID-19 Antibody Seroprevalence in Santa Clara  
496 County, California. medRxiv [Internet] 2020; Available from:  
497 <https://www.medrxiv.org/content/10.1101/2020.04.14.20062463v1.abstract>
- 498 24. USC-LA County Study: Early Results of Antibody Testing Suggest Number of COVID-19  
499 Infections Far Exceeds Number of Confirmed Cases in Los Angeles County [Internet]. [cited  
500 2020 Apr 25]; Available from:  
501 <http://publichealth.lacounty.gov/phcommon/public/media/mediapubhpdetail.cfm?prid=2328>
- 502 25. Menachemi N, Yiannoutsos CT, Dixon BE, et al. Population Point Prevalence of

- 503 SARS-CoV-2 Infection Based on a Statewide Random Sample - Indiana, April 25-29, 2020.  
504 MMWR Morb Mortal Wkly Rep 2020;69(29):960–4.
- 505 26. Biggs HM, Harris JB, Breakwell L, et al. Estimated Community Seroprevalence of  
506 SARS-CoV-2 Antibodies - Two Georgia Counties, April 28-May 3, 2020. MMWR Morb  
507 Mortal Wkly Rep 2020;69(29):965–70.
- 508 27. Davis HE, Assaf GS, McCorkell L, et al. Characterizing Long COVID in an international  
509 cohort: 7 months of symptoms and their impact [Internet]. bioRxiv. 2020;Available from:  
510 <http://medrxiv.org/lookup/doi/10.1101/2020.12.24.20248802>
- 511 28. Wentworth DN, Neaton JD, Rasmussen WL. An evaluation of the Social Security  
512 Administration master beneficiary record file and the National Death Index in the  
513 ascertainment of vital status. Am J Public Health 1983;73(11):1270–4.
- 514 29. NIH Begins Study to Quantify Undetected Cases of Coronavirus Infection | NIH: National  
515 Institute of Allergy and Infectious Diseases [Internet]. [cited 2020 Apr 12];Available from:  
516 [https://www.niaid.nih.gov/news-events/nih-begins-study-quantify-undetected-cases-coronav  
517 irus-infection](https://www.niaid.nih.gov/news-events/nih-begins-study-quantify-undetected-cases-coronavirus-infection)
- 518 30. Emory launches national COVID-19 home testing study to estimate infection and antibody  
519 rates in the U.S [Internet]. [cited 2020 Nov 30];Available from:  
520 <https://sph.emory.edu/news/news-release/2020/06/covid-vu-study.html>
- 521 31. Where the world builds software [Internet]. Github; [cited 2021 Jan 4]. Available from:  
522 <https://github.com/>
- 523 32. CHASING COVID Study Updates | CUNY ISPH [Internet]. CUNY ISPH. [cited 2020 Apr  
524 25];Available from: <https://cunyisph.org/chasing-covid-study-updates/>
- 525